💡 The inclusion of the P4 (Interim PET) parameter is significant because it allows doctors to adjust treatment mid-course based on how the tumor is actually responding to chemotherapy. Clinical Significance
High KBMP4 scores often signal that standard R-CHOP therapy may not be enough, potentially leading to more intensive consolidative strategies or clinical trials.
If you are looking for or comparisons to other models like the IPI or NCCN-IPI , I can provide those details. 💡 The inclusion of the P4 (Interim PET)
The model categorizes patients into three risk groups based on how many of these four parameters they meet: Risk Subgroup Criteria (Parameters met) Progression-Free Survival (PFS) Overall Survival (OS) 0 parameters Intermediate 1 or 2 parameters High-Risk 3 or more parameters
The model is a clinical scoring system used to predict the survival and prognosis of patients with de novo Diffuse Large B-cell Lymphoma (DLBCL) . The model categorizes patients into three risk groups
High proliferation index (Ki67 ≥ 70%) on immunohistochemistry. B (Bulky): Physical presence of a tumor mass ≥ 7.5 cm.
The name is an acronym for the four independent predictors it tracks: The name is an acronym for the four
Research indicates that variables like bulky disease and Ki67 are strong independent predictors of how long a patient will remain in remission.
